Eisai’s Alzheimer’s Drug To Launch In Japan For 25% Less Than US Price
Leqembi is set to be available from Dec. 20, with intravenous treatment expected to cost about $20,500 per patient yearly, compared to $26,000-plus in the U.S. Also in Japan, officials reported the country's first fatality from mpox.